RedHill Biopharma Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for RedHill Biopharma Ltd. (RDHL) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Operating Activities
Net Income-8.2723.92-71.67-97.74-76.17-42.30-38.82
Depreciation & Amortization0.621.998.1518.151.711.000.09
Stock Based Compensation0.671.655.6810.214.200.000.00
Change in Working Capital2.05-15.628.01-1.15-8.422.341.42
Change in Accounts Receivable0.0531.93-2.85-3.02-27.440.000.00
Change in Inventory0.742.393.80-8.29-4.640.000.00
Change in Accounts Payable-2.11-0.95-7.430.117.370.000.00
Change in Other Working Capital3.37-0.5414.4910.0433.130.000.00
Other Operating Activities-4.44-0.5420.655.4911.342.920.00
Net Cash from Operating Activities-9.37-35.82-29.19-65.05-65.42-36.07-34.46
Investing Activities
Capital Expenditures-0.01-0.01-0.20-0.1253.770.20-0.02
Purchases of Investments0.000.028.50-8.0318.130.000.00
Sales/Maturities of Investments0.000.028.500.48-53.37-4.335.41
Net Cash from Investing Activities-0.010.008.30-8.14-43.57-6.605.35
Financing Activities
Debt Repayment-0.64-1.18-1.48-1.68-1.61-0.800.00
Common Stock Issued8.2613.9623.8182.5423.8736.3041.90
Other Financing Activities0.798.66-10.88-7.40-16.000.00-0.50
Net Cash from Financing Activities8.4221.4411.4573.4684.3735.5141.76
Summary
Effect of Forex Changes on Cash0.01-0.02-0.08-0.100.000.00-0.10
Net Change in Cash-0.95-14.38-9.510.18-24.62-7.1612.65
Cash at Beginning of Period5.5719.9729.4729.3029.0229.0116.46
Cash at End of Period4.625.5719.9731.404.4021.8429.01
Free Cash Flow-9.38-35.83-29.38-65.16-119.19-36.28-34.52
Supplemental Disclosures
Interest Paid0.060.378.1811.286.650.000.00